Braveheart Bio, Inc.

Nasdaq: BRVE

Day 65 public/EARLY PUBLIC/IPO Aug 6, 2026/Pharmaceutical Preparations

$20.02

▲ 0.93 (+4.87%)

LIVE

updated 15h ago

Intelligence Core

MONITORING

No new filings in 72 h · watching for the next event

Current missionThesis Test · Day 31–90

Test the initial thesis against the first earnings, guidance and execution.

Focus

EarningsGuidanceExecutionInstitutional changes

CAUTIOUSFORMING THESIS…Intelligence score DERIVED

/ 100

Confidence65%

CURRENT THESIS INTERPRETED

Braveheart Bio, Inc. is an early public clinical-stage pharmaceutical company exhibiting high insider and institutional filing activity alongside negative net earnings and ongoing cash burn.

Momentum

Price · since IPOLIVE

Yahoo · 46 pts

H $30.00L $18.58Last $20.02

Current ThesisINTERPRETEDLIVE

Why

+High institutional interest indicated by 4 Schedule 13D/13G filings resulting in an institutional score of 93
+Active insider reporting with 29 insider forms filed since the IPO
+Positive 1-day momentum of 4.87% bringing the share price to $20.02

Risks

−Early public status with less than 90 days trading history
−Clinical-stage pharmaceutical sector risk combined with negative net income and reliance on balance sheet cash
−Elevated risk score of 78 driven by early public timeline and sector volatility

Catalysts

→Upcoming clinical pipeline updates disclosed through SEC filings
→Further institutional accumulation or dilution events observable via upcoming Schedule 13D/G filings

Current Thesis

Company Web Research · Official DomainVIEW ONLY

https://braveheart.bio

VIEW-ONLY

Visit

LIVE · SANDBOXED

Resolving official website…

Research EnvironmentLIVE

Research environment · $BRVESEC · market · news

22 evidence items|newest evidence 23d ago

Core activity · newest firstreal events · view-only

0s agoSCOREDERIVEDIntelligence score 67/100 recomputed from 5 rule-based signals.via Deterministic scoreDERIVED

0s agoSTATECore MONITORING · No new filings in 72 h · watching for the next event. Mission: Thesis Test.via Intelligence Core

15h agoOBSERVATIONVERIFIEDLast price $20.02 · +4.87% on the day.via Finnhub quoteVERIFIED

23d agoEVIDENCEBraveheart Bio to Participate in Stifel Cardiometabolic Forumvia Yahoo · tier 3, cross-check Sep 10, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D/A filed.via SEC EDGARVERIFIED 31d agoEVIDENCEBraveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Updatevia Yahoo · tier 3, cross-check 31d agoEVIDENCEThe Market Barely Knows These 2 IPO Stocks — Goldman Sachs Says ‘Buy’via Yahoo · tier 3, cross-check Sep 8, 2026EVIDENCEVERIFIEDForm 8-K filed · 8-K.via SEC EDGARVERIFIED Sep 8, 2026EVIDENCEVERIFIEDForm 10-Q filed · 10-Q.via SEC EDGARVERIFIED Aug 18, 2026EVIDENCEVERIFIEDForm SCHEDULE 13D filed.via SEC EDGARVERIFIED Aug 14, 2026EVIDENCEVERIFIEDForm 3 filed.via SEC EDGARVERIFIED

Evidence · SEC filing timelineVERIFIED

Filed	Form	Document	Source
2026-09-10	SCHEDULE 13D/A	Braveheart Bio, Inc.	SEC ↗
2026-09-08	10-Q	10-Q	SEC ↗
2026-09-08	8-K	8-K	SEC ↗
2026-08-18	SCHEDULE 13D	Braveheart Bio, Inc.	SEC ↗
2026-08-14	3	Braveheart Bio, Inc.

VERIFIEDfrom a primary sourceDERIVEDcomputed by rulesINTERPRETEDreasoned from evidence

Assembled 0s ago · every panel labelled live or simulated · no fabricated metrics